We aim at identifying the intestinal risk factors which control glycemia, dyslipidemia and heart failure.
We identified the first molecular mechanisms through that the gut hormone incretin GLP-1 control energy metabolism through the triggering of a gut-brain to periphery axis. The glucose transporter GLUT2, the GLP-1 receptor, the AMP-activated kinase are part of the mechanisms.
More recently we were the first to demonstrate that a change in diet i.e. a fat-enriched diet was responsible for the accumulation in the blood of lipopolysaccharides. We demonstrated that they were responsible for the triggering of metabolic inflammation leading to type 2 diabetes and obesity. Eventually, we identified that gut microbiota translocate from the mucosal layer of the intestine towards the tissues to establish a "tissue microbiota". The identification of the molecular mechanisms responsible for the translocation and for the control of the metabolic functions of the adipose tissue, the liver, the muscles and the endocrine pancreas are currently ongoing.
Eventually, the intestinal mechanisms such as SRB1 and the bile acids are currently been studied for their role of dyslipidemia. Animal models, and in vitro bioassays
As the metabolic control is a major determinant of heart failure we currently identify the molecular mechanisms within the intestine which are responsible for the control of the heart function.
While pioneering the role of gut microbiota on cardio and metabolic functions we translate these gain of knowledge in clinic and in biotechnology. Clinical trials are currently been performed and biotech companies are been set up based on preclinical and molecular discoveries.
Our team is composed of Clinicians, researchers, engineers, post doctoral fellows and PhD Students who are all dedicated to understand the molecular mechanisms within the intestine which are responsible for the control of cardio and metabolic phenotypes.
Clinical trials and biotech companies are been funded based on our discoveries